106 completed, 24 unknown, 15 terminated, 11 recruiting. 165 Phase 2, 24 Phase 3, 13 Phase 1.
Follow Nausea: new trials by email Literature Review of Nausea trials Research Report on Nausea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy Netupitant and Palonosetron, Dexamethasone, Olanzapine 5 Mg ORAL TABLET - Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 84 | 2026-11-02 | 2026-11-05 |
| Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Chinese Herbal Acupoint Application, Sham Acupoint Application, Standard Triple Antiemetic Therapy - Breast Neoplasms | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 190 | 2026-10-01 | 2026-09-30 |
| Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and Vomiting Fosrolapitant and Palonosetron for injection - Nausea and Vomiting Induced by Antibody-drug Conjugates (ADCs) | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 124 | 2026-07-15 | 2026-07-09 |
| Hyperemesis Gravidarum Risk Reduction With Metformin Metformin Extended Release Oral Tablet - Hyperemesis Gravidarum | Phase 1 / Phase 2 | Recruiting | University of Southern California | 224 | 2026-07-13 | 2026-07-22 |
| Midazolam Adjunct Therapy for Prevention of PONV in Gynecological Laparoscopy Midazolam 0.05 mg/kg IV as adjunct to dexamethasone and ondansetron for PONV prevention - Postoperative Nausea and Vomiting (PONV), Gynecological Laparoscopic Surgery | Phase 2 | Completed | Hameed Latif Hospital, Lahore | 300 | 2025-12-02 | 2026-06-25 |
| A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer LY3537021, Placebo, Standard of Care Antiemetic Therapies - Nausea, Vomiting | Phase 2 | Recruiting | Eli Lilly and Company | 204 | 2025-11-28 | 2026-11-04 |
| Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus Paclitaxel Auricular point stimulation plus dexamethasone - Nausea and Vomiting Caused by Chemotherapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 25 | 2025-11-25 | 2026-04-17 |
| Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab Deruxtecan Auricular point stimulation plus dexamethasone - Nausea and Vomiting Caused by Trastuzumab Deruxtecan | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 25 | 2025-11-25 | 2026-04-17 |
| Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Docetaxel Plus Cyclophosphamide Auricular point stimulation plus dexamethasone - Nausea and Vomiting Caused by Chemotherapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 25 | 2025-11-25 | 2026-04-17 |
| Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC) IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusion - Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy | Phase 2 | Recruiting | Helsinn Healthcare SA | 95 | 2025-07-07 | 2026-09-29 |
| Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery Encapsulated amisulpride 50 mg (matched for color, weight, smell and size), Encapsulated placebo (matched for color, weight, smell and size) - Post Operative Nausea and Vomiting (PONV) | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 276 | 2025-04-10 | 2026-09-09 |
| Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery Aprepitant, Placebo - Spinal Fusion, Nausea and Vomiting, Postoperative | Phase 2 | Recruiting | IWK Health Centre | 100 | 2025-03-17 | 2026-04-27 |
| A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use Tradipitant, Placebo - Obesity | Phase 2 | Completed | Vanda Pharmaceuticals | 124 | 2025-02-25 | 2025-11-12 |
| A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis. CIN-102 Dose 15mg, Placebo, CIN-102 Dose 10mg - Idiopathic Gastroparesis | Phase 2 | Completed | CinDome Pharma, Inc. | 416 | 2025-01-29 | 2026-07-13 |
| Effect of Magnesium Sulfate on Hemodynamics on Laparoscopic Cholecystectomy Patients Placebo, Magnesium - Hemodynamics Instability, Pain After Surgery | Phase 1 / Phase 2 | Completed | Ziauddin University | 60 | 2025-01-06 | 2026-09-02 |
| Antiemetic Fosaprepitant To Remedy Nausea and Vomiting Fosaprepitant 150 mg, Ondansetron 4 mg - Nausea and Vomiting, Nausea | Phase 2 / Phase 3 | Recruiting | Montefiore Medical Center | 200 | 2024-11-13 | 2026-05-18 |
| Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks, Ropivacaine with low, non weight based Dexamethasone additive - Postoperative Pain, Nausea and Vomiting, Postoperative | Phase 1 / Phase 2 | Active not recruiting | University of Arizona | 100 | 2024-10-10 | 2026-02-13 |
| Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting HSK21542, Dolasetron - Nausea and Vomiting, Chemotherapy-Induced | Phase 2 | Unknown | First Affiliated Hospital of Wenzhou Medical University | 180 | 2024-09-16 | 2024-09-19 |
| PONV Prevention Via Percutaneous Nerve Electrical Stimulation on PC6 electrical stimualtion via EmeTerm bracelet, antimetic drugs（ dexamethasone，ondansetron） - Postoperative Nausea and Vomiting | Phase 2 | Completed | Peking Union Medical College Hospital | 326 | 2024-02-05 | 2026-06-17 |
| Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients Amisulpride Injection, Dexamethasone - Nausea and Vomiting, Postoperative | Phase 2 / Phase 3 | Completed | Acacia Pharma Ltd | 453 | 2024-01-18 | 2025-06-25 |
Showing 20 of 165. Sign in to see all of them.
Vomiting (104) · Postoperative Nausea and Vomiting (58) · Pain, Postoperative (14) · Neoplasms (8) · Pain (8) · Breast Neoplasms (7) · Abdominal Pain (6) · Hyperemesis Gravidarum (5) · Migraine Disorders (5) · Colonic Neoplasms (4) · Gastroparesis (4) · Bile Duct Neoplasms (3) · Colorectal Neoplasms (3) · Constipation (3)
Pathological Conditions, Signs and Symptoms (165) · Signs and Symptoms (165) · Signs and Symptoms, Digestive (165) · Pathologic Processes (65) · Postoperative Complications (60) · Vomiting (41) · Neurologic Manifestations (33) · Neoplasms (24) · Pain (21) · Neoplasms by Site (20) · Digestive System Diseases (12) · Neoplasms by Histologic Type (12) · Nervous System Diseases (12) · Skin Diseases (11)
Dexamethasone (30) · Ondansetron (28) · Aprepitant (22) · Palonosetron (18) · Olanzapine (13) · Calcium Dobesilate (9) · Saline Solution (7) · ginger extract (6) · Granisetron (5) · fosaprepitant (5) · Acupuncture Therapy (4) · Dronabinol (4) · Dexmedetomidine (3) · Ringer's Lactate (3) · Sodium Chloride (3)
GlaxoSmithKline (5) · M.D. Anderson Cancer Center (5) · Second Affiliated Hospital, Zhejiang University, School of Medicine (4) · Acacia Pharma Ltd (3) · Assiut University (3) · Instituto do Cancer do Estado de São Paulo (3) · National Research Centre of Complementary and Alternative Medicine, Norway (3) · CinDome Pharma, Inc. (2) · Eisai Inc. (2) · Fudan University (2) · Gary Morrow (2) · Johns Hopkins University (2) · Merck Sharp & Dohme LLC (2) · NYU Langone Health (2) · National Institute of Hygiene and Epidemiology, Vietnam (2)
United States (76) · Canada (17) · China (13) · Egypt (9) · Brazil (7) · Germany (6) · Italy (6) · France (5) · Pakistan (5) · Denmark (4) · Hungary (4) · India (4) · Norway (4) · Poland (4) · Spain (4)
Arne Johan Norheim, PhD (2) · Jorge Cortes, MD (2) · Joseph Bubalo, PharmD, BCPS, BCOP (2) · Roger Chammas (2) · A. Riaz, MD (1) · Aaron P Hong, MD, FRCPC (1) · Agop Y. Bedikian, MD (1) · Ajeet Gajra, MD FACP (1) · Alana Koehler, MD (1) · Amani H Abdel-wahab, MD (1) · Andrea Myers, MD (1) · Angela M Sousa, MD, MsC, PhD (1) · Anh D Dang, PhD. (1)
PMID 34002866, PMID 12145072, PMID 12906958, PMID 15680647, PMID 16436839, PMID 16846542, PMID 17513629, PMID 17885699, PMID 19092351, PMID 19617379, PMID 19834961, PMID 20049561, PMID 20579837, PMID 20718754, PMID 21851346, PMID 22096279, PMID 22141732, PMID 22286518, PMID 22343090, PMID 22520120, PMID 22546895, PMID 22546966, PMID 22733373, PMID 23041302, PMID 23510951, PMID 23811424, PMID 23872464, PMID 23904932, PMID 24438599, PMID 24882606, PMID 25127659, PMID 25488303, PMID 25670522, PMID 25761431, PMID 25885838, PMID 25921377, PMID 27082959, PMID 27307177, PMID 27829428, PMID 28032216, PMID 28058142, PMID 28069044, PMID 28160217, PMID 28243404, PMID 29111115, PMID 29199141, PMID 31303716, PMID 31862004, PMID 32188417, PMID 32209630
2009 (1), 2019 (1), 2025 (1), P30CA046592 (1), P30CA069533 (1), R01HD076313 (1), R21HD105101 (1), U01DK065713 (1), U01DK073974 (1), U01DK073975 (1), U01DK073983 (1), U01DK073985 (1), U01DK074007 (1), U01DK074008 (1), U01DK074035 (1)